First-in-human study of 225Ac-PSMA-Trillium (BAY 3563254) in participants with advanced metastatic castration-resistant prostate cancer (mCRPC)
22049
Phase 1 other active
Quick answer
First-in-human study of 225Ac-PSMA-Trillium (BAY 3563254) in participants with advanced metastatic castration-resistant prostate cancer (mCRPC) for Advanced metastatic castration-resistant prostate cancer with prostate specific membrane antigen (PSMA) expression is a Phase 1 program (other) at Bayer Schering Pharma AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bayer Schering Pharma AG
- Indication
- Advanced metastatic castration-resistant prostate cancer with prostate specific membrane antigen (PSMA) expression
- Phase
- Phase 1
- Modality
- other
- Status
- active